Todd Flannery, MD
Radiation Oncology · Langhorne, PANPI 1033253679
Payments from drug & device makers
Across 29 payments — averaging $49.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$197
- Novocure Inc.$143
- Exelixis Inc.$128
- Epizyme, Inc.$125
- Karyopharm Therapeutics Inc.$125
- AstraZeneca$120
- plus $589 from 15 others
What the payments were for
- Food & beverage$1,428100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 4 | $197 |
| Novocure Inc. | 1 | $143 |
| Exelixis Inc. | 1 | $128 |
| Epizyme, Inc. | 1 | $125 |
| Karyopharm Therapeutics Inc. | 1 | $125 |
| AstraZeneca | 2 | $120 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| Blueprint Medicines Corporation | 1 | $93 |
| Amgen | 1 | $90 |
| Pfizer | 2 | $59 |
| AbbVie | 3 | $53 |
| Boston Scientific | 2 | $44 |
| Tempus AI, Inc | 1 | $24 |
| Seagen Inc. | 1 | $20 |
| Springworks Therapeutics, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Gilead | 1 | $15 |
| GSK | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Myovant Sciences Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,428 in reported general payments places this provider in the 65th percentile of 339 radiation oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $770 |
| Tamsulosin Hcl | 13 | $215 |
| Sodium FluorideFluoride (Sodium) | 12 | $175 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Langhorne
- David ClumpPittsburgh$3.2M
- Wenyin ShiPhiladelphia$1.1M
- Amit MaityPhiladelphia$1.1M
- Joseph CasterPhiladelphia$1M
- Abigail BermanPhiladelphia$924K
- Mitchell MachtayHershey$741K
- John PlastarasPhiladelphia$538K
- Justin BekelmanPhiladelphia$490K
- James MetzPhiladelphia$458K
- Andy MinnPhiladelphia$457K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.